Abstract
ABSTRACT Introduction : This study aims to determine the effect of varying gadopentetate dimeglumine (Gd-DTPA) dose on Dynamic Contrast Enhanced-Magnetic Resonance Imaging (DCE-MRI) tracking of brain tumor photodynamic therapy (PDT) outcome. Methods : We injected 2.5 x 10 5 U87 cells (derived from human malignant glioma) into the brains of six athymic nude rats. After 9, 12, and 13 days DCE-MRI images were acquired on a 9.4 T micro-MRI scanner before and after administration of 100, 150, or 200 P L of Gd-DTPA. Results : Tumor region normalized DCE-MRI scan enhancement at peak was: 1.217 over baseline (0.018 Standard Error [SE]) at the 100 P L dose, 1.339 (0.013 SE) at the 150 P L dose, and 1.287 (0.014 SE) at the 200 P L dose. DCE-MRI peak tumor enhancement at the 150 P L dose was significantly greater than both the 100 P L dose ( p < 3.323E-08) and 200 P L dose ( p < 0.0007396). Discussion : In this preliminary study, the 150 P L Gd-DTPA dose provided the greatest T1 weighted contrast enhancement, while minimizing negative T2* effects, in DCE-MRI scans of U87-derived tumors. Maximizing Gd-DTPA enhancement in DCE-MRI scans may assist development of a clinically robust (i.e., unambiguous) technique for PDT outcome assessment. Keywords : brain, cancer, Dynamic Contrast Enhanced-Magnetic Resonance Imaging (DCE-MRI), gadopentetate dimeglumine (Gd-DTPA), glioma, neurosurgery, photodynamic therapy (PDT).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.